Treats nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus…. ANDA 77652, held by Zydus Lifesciences. Levofloxacin.
As of Nov 16, 2026, ANDA 77652 (Levofloxacin), held by Zydus Lifesciences, was first approved by FDA on Sep 7, 2012, with 11 approved supplements and 0 published complete response letters.
Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated ( 1, 12.4 ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 7, 2012 | Original application | Approved | None posted |
| Levofloxacin250MG · tablet;oral | Levofloxacin | Rx |
| Levofloxacin500MG · tablet;oral | Levofloxacin | Rx |
| Levofloxacin750MG · tablet;oral | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 20Labeling · Standard review | Approved | None posted |
| Jun 28, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Apr 4, 2022 | Supplement 19Manufacturing | Approved | None posted |
| May 29, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 16Labeling · Standard review | Approved | None posted |
| Apr 16, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 16, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 16, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 16, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 25, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 25, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 7, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters